Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25091488 | 0.83 | DDB1 (0.71) | DDB1CRBN | |
| SCHEMBL25567159 | 0.83 | DDB1 (0.71) | DDB1CRBN | |
| SCHEMBL24480350 | 0.82 | DDB1 (0.70) | DDB1CRBN | |
| SCHEMBL21946764 | 0.81 | DDB1 (0.68) | DDB1CRBN | |
| SCHEMBL24890782 | 0.81 | DDB1 (0.68) | DDB1CRBN | |
| SCHEMBL31101846 | 0.80 | DDB1 (0.67) | DDB1CRBN | |
| SCHEMBL31103065 | 0.80 | DDB1 (0.67) | DDB1CRBN | |
| SCHEMBL31101070 | 0.80 | DDB1 (0.67) | DDB1CRBN | |
| SCHEMBL27167860 | 0.79 | DDB1 (0.67) | DDB1CRBN | |
| Hydrochloric Acid SCHEMBL29279132 | 0.78 | DDB1 (0.66) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | DDB1 323/4885CRBN 42/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885 |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.